Diagnostic & Medical Laboratories in European Union 2026: Industry Statistics & Trends

The diagnostic and medical laboratories industry in the European Union provides vital routine testing, advanced molecular pathologies, and diagnostic imaging necessary for clinical decision-making. Operating within a heavily regulated public-private framework, the sector is currently undergoing significant post-pandemic consolidation and digital transformation. Major multinational operators drive clinical outcomes across member states, processing millions of samples annually as evidenced by private operations such as SYNLAB AG which reported a revenue of 2.62 billion EUR in 2024 (SYNLAB ESG Data Book 2024). The industry is navigating long-term strategic adjustments fueled by shifting Europea

Industry snapshot

Key public data points

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Diagnostic & Medical Laboratories in European Union industry cover?

The diagnostic and medical laboratories industry comprises independent facilities and specialized hospital departments dedicated to analyzing biological samples and providing medical imaging. These operations are vital for disease screening, diagnosis, risk assessment, and treatment monitoring across healthcare paths.

• •Classified officially under the European NACE Rev. 2 system within code 86.90 for other human health activities.
• •Includes diverse services ranging from basic clinical chemistry and hematology to advanced genetic sequencing and histopathology.
• •Encompasses both standalone commercial testing facilities and integrated public hospital laboratory networks.

Who operates in the industry and how is it structured?

The European laboratory market is structurally divided between public healthcare systems, which process a high volume of hospital-based diagnostics, and private commercial laboratories. Private networks operate via a hub-and-spoke model where routine processing is centralized to maximize capital efficiency.

• •Large-scale laboratory infrastructure acts as a primary cost-saving mechanism for regional public insurance systems.
• •The infrastructure relies on massive procurement agreements for diagnostic instruments and reagents from global life sciences manufacturers.
• •Logistical networks are highly advanced, moving biospecimens safely across borders under tight timelines to central processing facilities.

What drives demand in the industry?

Demand is fundamentally underpinned by the long-term demographic shift toward an aging population across the European Union. Chronic disease prevalence and a policy focus on preventative screening significantly increase testing frequency per capita.

• •Eurostat personnel figures show an estimated 1.98 million practicing physicians across the EU in 2023, driving steady diagnostic testing demand.
• •An increasing volume of oncology and immunology therapies requires specialized companion diagnostics to qualify patients for treatment.
• •EU member state national health programs are expanding routine screening mandates for metabolic and cardiovascular illnesses.

Who are the notable companies in the industry?

The European landscape features intense competition among a few dominant multinational consolidators alongside regional private practices. Market leaders utilize aggressive mergers and acquisitions to capture market share and achieve local scale economies.

• •SYNLAB AG is a primary market participant, operating in over 20 countries and achieving revenues of 2.62 billion EUR in 2024.
• •Eurofins Scientific SE expanded its diagnostic footprint by closing 40 business combinations in 2025, including the acquisition of Synlab's clinical diagnostics operations in Spain.
• •Sonic Healthcare Limited, an international diagnostics provider, completed a major European expansion by acquiring Germany's Laboratory Group Dr. Kramer & Colleagues (LADR) for an enterprise value of 423 million EUR in 2025.
• •Unilabs, operating state-of-the-art diagnostic and imaging facilities across 16 countries, generates annual revenues of approximately 2 billion EUR.

What are the recent trends and outlook?

The post-pandemic landscape is defined by margin pressures stemming from inflation, labor shortages, and reduced state reimbursements for standard tests. Operators are countering these trends through investments in automated laboratory tracks and digital pathology workflows.

• •Commercial networks are rapidly divesting underperforming non-core entities to reallocate capital toward higher-margin specialized genetics.
• •Automation and artificial intelligence implementation are growing to mitigate the shortage of certified medical laboratory technicians.
• •Laboratory groups are setting verified environmental goals, with firms like Eurofins Scientific SE reducing absolute carbon emissions by 7% in 2025.

How is the industry regulated?

Laboratories must comply with complex and changing regulatory frameworks overseen by both European authorities and national accreditation bodies. Quality management mandates dictate strict operational standards for technical competency, safety, and equipment calibration.

• •Operations are subject to the rigorous European In Vitro Diagnostic Medical Devices Regulation (IVDR), which impacts laboratory-developed tests.
• •Facilities must achieve and maintain certification under ISO 15189 standards to ensure the competence and quality of medical laboratories.
• •The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) routinely advocates for harmonized analytical procedures and measurement units across the union.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Healthcare Personnel Statistics 2023 ·
• SYNLAB ESG Data Book 2024 ·
• Eurofins Scientific SE Full Year 2025 Results ·
• Sonic Healthcare Annual Report 2025 ·
• European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Essentials 2024-2025